As naloxegol nears end zone, Nektar seeks $108.4M for pipeline
By Marie Powers
Thursday, January 23, 2014
After pocketing a $70 million milestone payment from partner Astrazeneca plc in November following the FDA’s acceptance of the new drug application (NDA) for lead compound naloxegol, Nektar Therapeutics Inc. turned to the public markets in a big way to advance its internal programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.